Retrieve available abstracts of 21 articles: HTML format
Single Articles
June 2025
STITZ R, Stoiber F, Silye R, Rebhan E, et al Clinical impact of real-time androgen receptor alteration monitoring on
metastatic castration-resistant prostate cancer treatment in real-world settings.
Int J Cancer. 2025 Jun 25. doi: 10.1002/ijc.70019. PubMedAbstract available
SAWADA Y, Kikugawa T, Onishi T, Arai O, et al CTHRC1 promotes bone metastasis in prostate cancer.
Int J Cancer. 2025 Jun 21. doi: 10.1002/ijc.70012. PubMedAbstract available
December 2024
SIECH C, de Angelis M, Jannello LMI, Di Bello F, et al Life expectancy in rare histological prostate cancer subtypes.
Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35323. PubMedAbstract available
MCGRATH CB, Shreves AH, Shanahan MR, Guard HE, et al Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of
risk factors.
Int J Cancer. 2024 Dec 11. doi: 10.1002/ijc.35279. PubMedAbstract available
October 2024
GRENVILLE ZS, Noor U, Rinaldi S, Gunter MJ, et al Perturbations in the blood metabolome up to a decade before prostate cancer
diagnosis in 4387 matched case-control sets from the European Prospective
Investigation into Cancer and Nutrition.
Int J Cancer. 2024 Oct 8. doi: 10.1002/ijc.35208. PubMedAbstract available
September 2024
MOGHUL M, Tran A, Croft F, Kinsella N, et al The Man Van: A pilot study of using mobile targeted case-finding to address
health inequalities in prostate cancer.
Int J Cancer. 2024 Sep 4. doi: 10.1002/ijc.35169. PubMedAbstract available
July 2024
BUCK SAJ, Talebi Z, Drabison T, Jin Y, et al Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
Int J Cancer. 2024;155:314-323. PubMedAbstract available
June 2024
HUANG CY, Huang CP, Huang YY, Huang SK, et al Real-world safety and effectiveness of radium-223 in patients with metastatic
castration-resistant prostate cancer: Interim analyses of the prospective,
observational RAPIT study.
Int J Cancer. 2024 Jun 26. doi: 10.1002/ijc.35040. PubMedAbstract available
SEE AW, Conway P, Frydenberg M, Haxhimolla H, et al Five-year outcomes of fractionated stereotactic body radiotherapy for
oligometastatic prostate cancer from the TRANSFORM phase II trial.
Int J Cancer. 2024 Jun 19. doi: 10.1002/ijc.35052. PubMedAbstract available
April 2024
LUO Y, Yu J, Lin Z, Wang X, et al Metabolic characterization of sphere-derived prostate cancer stem cells reveals
aberrant urea cycle in stemness maintenance.
Int J Cancer. 2024 Apr 22. doi: 10.1002/ijc.34967. PubMedAbstract available
WEISS S, Lamy P, Rusan M, Norgaard M, et al Exploring the tumor genomic landscape of aggressive prostate cancer by
whole-genome sequencing of tissue or liquid biopsies.
Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34949. PubMedAbstract available
March 2024
STROMBERG U, Berglund A, Carlsson S, Thellenberg Karlsson C, et al Socioeconomic inequality in prostate cancer diagnostics, primary treatment,
rehabilitation, and mortality in Sweden.
Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34932. PubMedAbstract available
LEHTO TK, Pylvalainen J, Sandeman K, Kenttamies A, et al Histomic and transcriptomic features of MRI-visible and invisible clinically
significant prostate cancers are associated with prognosis.
Int J Cancer. 2024;154:926-939. PubMedAbstract available
ZHANG Y, Stopsack KH, Song M, Mucci LA, et al Healthy dietary patterns and risk of prostate cancer in men at high genetic risk.
Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34898. PubMedAbstract available
February 2024
CARUANA M, Gulati R, Etzioni R, Barratt A, et al Benefits and harms of prostate specific antigen testing according to Australian
guidelines.
Int J Cancer. 2024;154:648-658. PubMedAbstract available
January 2024
SCHUURMAN MS, Lemmens VEPP, Portielje JEA, van der Aa MA, et al The cancer burden in the oldest-old: Increasing numbers and disparities-A
nationwide study in the Netherlands, 1990 to 2019.
Int J Cancer. 2024;154:261-272. PubMedAbstract available
ZAHED H, Feng X, Sheikh M, Bray F, et al Age at diagnosis for lung, colon, breast and prostate cancers: An international
comparative study.
Int J Cancer. 2024;154:28-40. PubMedAbstract available
November 2023
RANGANATHAN S, Dee EC, Debnath N, Patel TA, et al Access and barriers to genomic classifiers for breast cancer and prostate cancer
in India.
Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34784. PubMedAbstract available
NG HUNG SHIN B, Tan S, Rhee H, Chung E, et al Impact of the COVID-19 pandemic on delivery of prostate cancer care in Australia:
An interrupted time series analysis.
Int J Cancer. 2023 Nov 3. doi: 10.1002/ijc.34759. PubMedAbstract available
FREI K, Schecher S, Daher T, Horner N, et al Inhibition of the Cyclin K-CDK12 complex induces DNA damage and increases the
effect of androgen deprivation therapy in prostate cancer.
Int J Cancer. 2023 Nov 2. doi: 10.1002/ijc.34778. PubMedAbstract available
October 2023
ALMURADOVA E, Seyyar M, Arak H, Tamer F, et al The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in
metastatic castration-resistant prostate cancer: Turkish Oncology Group
multicenter study.
Int J Cancer. 2023 Oct 11. doi: 10.1002/ijc.34749. PubMedAbstract available